Trials / Completed
CompletedNCT05826028
Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 368 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was a retrospective, non-interventional, longitudinal, descriptive study. This study did not have a key underlying hypothesis, rather it was designed to explore the onboarding and adherence of SPMS patients in Australia to Mayzent (siponimod) treatment. Initiating siponimod involves pre-screen tests, including a CYP2C9 genotype test to determine siponimod maintenance dosing, and patients underwent a 6-day titration prior to maintenance. The MSGo platform was developed to support onboarding. It is an integrated digital platform that functions as a patient support service.
Conditions
Timeline
- Start date
- 2020-07-09
- Primary completion
- 2022-04-20
- Completion
- 2022-04-20
- First posted
- 2023-04-24
- Last updated
- 2023-04-24
Locations
2 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT05826028. Inclusion in this directory is not an endorsement.